Want to see LCTX full AI Analyst Report?
Total Valuation
Lineage Therap has a market cap or net worth of $321.59M. The enterprise value is $278.08M.
Market Cap$321.59M
Enterprise Value$278.08M
Share Statistics
Lineage Therap has 249,298,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding249,298,300
Owned by Insiders13.98%
Owned by Institutions2.67%
Financial Efficiency
Lineage Therap’s return on equity (ROE) is -1.43 and return on invested capital (ROIC) is -19.75%.
Return on Equity (ROE)-1.43
Return on Assets (ROA)-0.56
Return on Invested Capital (ROIC)-19.75%
Return on Capital Employed (ROCE)-0.22
Revenue Per Employee194.08K
Profits Per Employee-847.11K
Employee Count75
Asset Turnover0.13
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lineage Therap is ―. Lineage Therap’s PEG ratio is -0.03.
PE Ratio―
PS Ratio26.40
PB Ratio8.63
Price to Fair Value8.63
Price to FCF-19.77
Price to Operating Cash Flow-14.24
PEG Ratio-0.03
Income Statement
In the last 12 months, Lineage Therap had revenue of 14.56M and earned -63.53M in profits. Earnings per share was -0.28.
Revenue14.56M
Gross Profit13.71M
Operating Income-21.78M
Pretax Income-68.65M
Net Income-63.53M
EBITDA-67.95M
Earnings Per Share (EPS)-0.28
Cash Flow
In the last 12 months, operating cash flow was -22.11M and capital expenditures -192.00K, giving a free cash flow of -22.30M billion.
Operating Cash Flow-22.11M
Free Cash Flow-22.30M
Free Cash Flow per Share-0.09
Dividends & Yields
Lineage Therap pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.17
52-Week Price Change24.27%
50-Day Moving Average1.30
200-Day Moving Average1.59
Relative Strength Index (RSI)48.31
Average Volume (3m)1.77M
Important Dates
Lineage Therap upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Lineage Therap as a current ratio of 5.20, with Debt / Equity ratio of 4.44%
Current Ratio5.20
Quick Ratio5.20
Debt to Market Cap0.00
Net Debt to EBITDA0.56
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lineage Therap has paid -5.11M in taxes.
Income Tax-5.11M
Effective Tax Rate0.07
Enterprise Valuation
Lineage Therap EV to EBITDA ratio is -5.09, with an EV/FCF ratio of -17.79.
EV to Sales23.76
EV to EBITDA-5.09
EV to Free Cash Flow-17.79
EV to Operating Cash Flow-18.28
Balance Sheet
Lineage Therap has $53.38M in cash and marketable securities with $2.39M in debt, giving a net cash position of $50.99M billion.
Cash & Marketable Securities$53.38M
Total Debt$2.39M
Net Cash$50.99M
Net Cash Per Share$0.20
Tangible Book Value Per Share<$0.01
Margins
Gross margin is 97.98%, with operating margin of -149.62%, and net profit margin of -436.47%.
Gross Margin97.98%
Operating Margin-149.62%
Pretax Margin-471.61%
Net Profit Margin-436.47%
EBITDA Margin-466.80%
EBIT Margin-471.61%
Analyst Forecast
The average price target for Lineage Therap is $7.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$7.00
Price Target Upside309.36% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast54.64%
EPS Growth Forecast-250.94%